ARIA digital anamorphosis: digital transformation of health and care in airway diseases from research to practice

Accepted/In Press date: 8 June 2020

e-pub ahead of print date: 8 June 2020

Published date: 1 January 2021

Additional Information: Funding Information: MA reports personal fees from POCI‐01‐0145‐FEDER‐029130 mINSPIRERS—mHealth to measure and improve adherence to medication in chronic obstructive respiratory diseases—generalization and evaluation of gamification, peer support and advanced image processing technologies from ERDF (European Regional Development Fund) funded by the COMPETE2020 and by National Funds through FCT (Fundação para a Ciência e a Tecnologia). EB reports personal fees from Novartis, Menarini, ALK, Sanofi Regeneron, Boehringer Ingelheim, AstraZeneca, Sanofi Genzyme, Orion, and is a member of the Science Committee and Board of the Global Initiative for Asthma (GINA). PB reports personal fees and other from Roche, Boehringer and Novartis, personal fees from AstraZeneca and TEVA, and other from Chiesi and Stallergenes. LPB reports research grants for participation to multicentre studies from AstraZeneca, Boston Scientific, GlaxoSmithKline, Hoffman La Roche, Novartis, Ono Pharma, Sanofi and Takeda, support for research projects introduced by the investigator from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck and Takeda, fee for consulting and advisory boards from Astra Zeneca, Novartis and Methapharm, nonprofit grants for production of educational materials from AstraZeneca, Boehringer‐Ingelheim, GlaxoSmithKline, Merck and Novartis, conference fees from AstraZeneca, GlaxoSmithKline, Merck and Novartis, and support for participation in conferences and meetings from Novartis and Takeda. JB reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi Aventis, Takeda, Teva, and Uriach, and other from KYomed INNOV. RB reports personal fees from AstraZeneca, Chiesi, Cipla, Sanofi and Teva, grants and personal fees from Boehringer Ingelheim, Novartis and Roche, and grants from GlaxoSmithKline, all outside the submitted work. VC reports personal fees from ALK, Allergopharma, Allergy Therapeutics, Diater, LETI, Thermo Fisher and Stallergenes. JCS reports other from Boehringer Ingelheim, GSK, personal fees, nonfinancial support and other from AstraZeneca, personal fees and other from Mundipharma. AC reports personal fees from Novartis, Regeneron, Thermo Fisher Scientific, Philips and Sanofi. ME reports personal fees from DBV Technologies and Mylan. JF reports being a partner in a company developing mobile technologies for monitoring airways diseases. EH reports personal fees from AstraZeneca, Novartis, GSK, Sanofi Genzyme, Teva, Circassia and Nestlè Purina. GI is consultant for Amicus Therapeutics and received a research grant from Amicus therapeutics. PK reports personal fees from Aflofarm, Fresenius, Lek‐AM, Novartis, Polpharma and Sandoz, grants from European Union, European Commission. LK reports personal fees from Allergopharma, HAL Allergie, ALK‐Abelló, LETI Pharma, Allergy Therapeutics, Stallergenes, Quintiles, AstraZeneca, GSK, ASIT biotech and Lofarma, and grants and personal fees from MEDA/Mylan and Sanofi. DLL reports personal fees from Armstrong, Astrazeneca, Boehringer Ingelheim, Chiesi, DBV Technologies, Grunenthal, GSK, MEDA, Menarini, MSD, Novartis, Pfizer, Novartis, Sanofi, Siegfried and UCB, grants from Sanofi, Astrazeneca, Novartis, UCB, GSK, TEVA, Boehringer Ingelheim and Chiesi. RL reports grants and personal fees from GSK, from AZ and Novartis and grants from Chiesi. Dr Loureiro reports personal fees from AstraZeneca, Novartis, GSK, Sanofi, TEVA and Menarini. JM reports personal fees and nonfinancial support from Novartis, Sanofi, AstraZeneca and Immunotek. MM reports grants and personal fees from Aralez, AstraZeneca, FAES, Genentech, Novartis, MSD, Roche, Sanofi, UCB and Uriach. JM reports personal fees from ALK‐Abelló, Sanofi Genzyme & Regeneron, Menarini Group, MSD, Mitsubishi‐Tanabe, Novartis, UCB Pharma, and GENENTECH—Roche, grants and personal fees from URIACH Group, MYLAN‐MEDA Pharma. AM reports personal fees from Aimmune, DVB, Nestlè Health Institute and Nestlè Purina. BN reports other from Co‐founded AsthmaTuner, eHealth system for asthma. YO reports personal fees from Kyowa Co., Ltd, Eizai Co., Ltd, Shionogi Co., Ltd., Torii Co., Ltd., GSK and MSD, grants and personal fees from Kyorin Co., Ltd., and Tiho Co., Ltd., grants from Yakuruto Co., Ltd., and Yamada Bee Farm. NP reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES FARMA, Sanofi, Mylan/Meda, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH and Boehringer Ingelheim, and grants from Gerolymatos International SA and Capricare. JLP reports grants and personal fees from Air Liquide Foundation, Agiradom, AstraZeneca, Philips and ResMed, grants from Fisher and Paykel, Mutualia and Vitalaire, personal fees from Boehringer Ingelheim, Jazz pharmaceutical, Night Balance and Sefam. DP reports personal fees, nonfinancial support and other from Revenio, grants and personal fees from GlaxoSmithKline, personal fees from Merck and Sandoz, other from Boehringer Ingelheim, Novartis, MSD and Chiesi, nonfinancial support from Menarini, nonfinancial support from Pharmas, and personal fees and nonfinancial support from Salveo. DP reports personal fees from Amgen, Mundipharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Cipla, GlaxoSmithKline, Kyorin and Thermo Fisher, grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia and Mylan, grants from Respiratory Effectiveness Group, Sanofi Genzyme, Teva and Theravance, grants from UK National Health Service, nonfinancial support from Efficacy and Evaluation Mechanism Programme, Health Technology Assessment and stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals, and owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore). FP has been scientific consultant, researcher and speaker supported by the following commercial companies: Menarini, Alk‐Abello, Almirall, Allergy Therapeutics, Anallergo, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GSK, Hal Allergy, Lab. Guidotti, Lofarma, Malesci, MSD, Mundipharma, Novartis, Roche, Sanofi, Stallergenes and Valea. Dr Sastre is consultant for Thermo Fisher, Hycor, Novartis, Sanofi, Leti, Mundipharma, ALK and GSK, paid conferences from Novartis, GSK, Circassia, Sanofi, LETI and FAES FARMA, and research grants from Thermo Fisher, Mundipharma, ALK, Sanofi. GS reports personal fees from ALK, Mylan and ALK and other from Rhinology & Laryngology Research Fund, BSACI and EAACI. MS reports fees from ASIT Biotech.sa, ALK and Allergopharma. AMTB reports grants and personal fees from Novartis, Sanofi, Mundipharma, GSK (GlaxoSmithKline) and Teva Pharma, personal fees from AstraZeneca, grants from Boehringer Ingelheim, outside the submitted work. IT reports personal fees from Honoraria for educational activities, speaking engagements, advisory boards from Boehringer Ingelheim, Astra Zeneca, GSK and Novartis and grants from GSK Hellas and Elpen. MW reports personal fees from ALK‐Abello, AstraZeneca, Bencard Allergie, HAL Allergy, Leti Pharma, Meda Pharma, Novartis, Sanofi Aventis, Stallergenes and Teva. SW reports personal fees and other from CSL Behring, Shire, AstraZeneca, Teva, Meda, Merck, GSK and Novartis, personal fees from Pediapharm, Aralez, Sanofi and Stallergenes. The other authors have no conflict of interest to declare. Publisher Copyright: © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Keywords: ARIA, CARAT, MASK, asthma, digital transformation of health and care, rhinitis

Local EPrints ID: 442000

URI: http://eprints.soton.ac.uk/id/eprint/442000

DOI: doi:10.1111/all.14422

ISSN: 0105-4538

PURE UUID: 038792f7-d47a-4c73-ab24-1dceda9eba08

ORCID for Graham Roberts: orcid.org/0000-0003-2252-1248

Date deposited: 03 Jul 2020 16:38

Last modified: 17 Mar 2024 05:39